“No End In Sight” For Completing OTC Monographs – CDER Director Woodcock
This article was originally published in The Tan Sheet
Executive Summary
Janet Woodcock says FDA expected when the process was launched to complete all monographs by the year 2000, but 25 remain in tentative final monograph status, with a rulemaking required to finalize each one. “The rulemaking process … doesn’t work for getting monographs done in a very timely manner,” she says.
You may also be interested in...
Hatch Closing Act: OTC Monograph Reform Legislation?
The Utah Republican has been instrumental during his more than 40 years in office in passing legislation central to the growth of the OTC drug and dietary supplement industries. But the expansion of the OTC market is stifled by FDA's monograph system for making more ingredients available, a process agency officials say no longer works.
Hatch Closing Act: OTC Monograph Reform Legislation?
The Utah Republican has been instrumental during his more than 40 years in office in passing legislation central to the growth of the OTC drug and dietary supplement industries. But the expansion of the OTC market is stifled by FDA's monograph system for making more ingredients available, a process agency officials say no longer works.
'Not As Easy' OTC Codeine Label Changes Worry FDA Rx Product Advisors
FDA officials acknowledge at the Pediatric Advisory Committee Sept. 11 that labeling restrictions for opioid-containing Rx antitussives for pediatric cough wouldn't apply to labeling for codeine cough products available under an OTC monograph.